In This Article:
-
BIOCERA-VET® (whole line) units sold are up 99% Year-on-Year & up 27% Quarter-over-Quarter in Q4 2023; they are up 90% Year-on-Year for H2 2023
-
BIOCERA-VET® OSTEOSARCOMA unit sales up 145% Year-on-Year for H2 2023 and up 38% Quarter-over-Quarter in Q4 2023
GOSSELIES, Belgium & WALLONIA, Belgium, January 23, 2024--(BUSINESS WIRE)--Regulatory News:
TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces significant sales progression for its BIOCERA-VET® product range in the 4th quarter of 2023 year-on-year and quarter over quarter.
The number of BIOCERA-VET® units sold increased 99% in the fourth quarter of 2023 as compared to the same period in 2022 and 27% as compared to the third quarter of 2023. Over the second half of 2023, BIOCERA-VET® units sold progressed 90% as compared to the same period of 2022.
BIOCERA-VET® BONE SURGERY1 accounted for 80% of the units sold and BIOCERA-VET® OSTEOSARCOMA RTU for the remaining 20%. As for the third quarter, BONE SURGERY RTU 3x1cc and OSTEOSARCOMA RTU 2x12cc have significantly contributed to these figures. BIOCERA-VET® COMBO CLEAN launched in Europe and United-States in May and October 2023 respectively already accounted for 5% of a total unit sold in 2023. In the 4th quarter of 2023, BIOCERA-VET® BONE SURGERY unit sales were up 101% compared to the same period of 2022 and up 24% compared to previous quarter; they increased 80% over 2H 2023 as compared to H2 2022.
BIOCERA-VET® OSTEOSARCOMA RTU sales increased 145% Year-on-Year over the second half of 2023, and 38% Quarter-over-Quarter for the 4th quarter 2023.
Rapidly progressing, North America (USA and Canada) represents 21% of the units sold over the 2H 2023 (vs. 12% in H2 2022).
As communicated, the Company continued its important commercial efforts during the last quarter 2023 resulting in a continue progression of the sales.
Enrico Bastianelli, Chief Executive Officer of TheraVet, stated: "The very good figures of fourth quarter 2023 confirm the positive sales dynamic reported for the previous quarter. Our commercial and marketing efforts resulted in significant progression of the sales. The Company took advantage of this positive trend to continue the expansion of the distribution in Europe already started with Italy and Germany recently but also on expanding its product portfolio in 2024."
About TheraVet SA
TheraVet is a veterinary biotechnology company specializing in osteoarticular treatments for companion animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from joint and bone diseases. For pet owners, the health of their pets is a major concern and TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris and Brussels, has its head office in Belgium (Gosselies) with a US subsidiary.
For more information, visit the TheraVet website or follow us on LinkedIn / Facebook / Twitter